| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 472 |
| 1 | IPILIMUMAB | 433 |
| 2 | PEMBROLIZUMAB | 229 |
| 3 | CARBOPLATIN | 168 |
| 4 | PACLITAXEL | 111 |
| 5 | HYDROCORTISONE | 109 |
| 6 | HYDROCORTISONE ACETATE | 101 |
| 7 | ANTI ITCH | 96 |
| 8 | ANTI-ITCH | 96 |
| 9 | ANTI-ITCH CREAM | 96 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AVANAFIL | 1 | 0.0143 |
| 1 | DIPHENHYDRAMINE HYDROCHLORIDE AND ZINC ACETATE | 1 | 0.0132 |
| 2 | IPILIMUMAB | 433 | 0.0099 |
| 3 | TETANUS IMMUNE GLOBULIN (HUMAN) | 1 | 0.0092 |
| 4 | REMIMAZOLAM BESYLATE | 1 | 0.0090 |
| 5 | CEFOTETAN DISODIUM | 1 | 0.0089 |
| 6 | TREMELIMUMAB | 35 | 0.0079 |
| 7 | DEXTROSE AND SODIUM CHLORIDE | 1 | 0.0060 |
| 8 | SOMAPACITAN-BECO | 1 | 0.0055 |
| 9 | DESMOPRESSIN ACETATE | 20 | 0.0052 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 772 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 466 |
| 2 | Corticosteroid [EPC] | 247 |
| 3 | Platinum-based Drug [EPC] | 214 |
| 4 | Microtubule Inhibitor [EPC] | 120 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 94 |
| 6 | Alkylating Drug [EPC] | 82 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 73 |
| 8 | Kinase Inhibitor [EPC] | 70 |
| 9 | Benzodiazepine [EPC] | 55 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 466 | 0.0097 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 772 | 0.0078 |
| 2 | Melanocortin 4 Receptor Agonist [EPC] | 1 | 0.0035 |
| 3 | Dihydrofolate Reductase Inhibitor Antimalarial [EPC] | 4 | 0.0031 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 46 | 0.0021 |
| 5 | Recombinant Human Growth Hormone [EPC] | 42 | 0.0019 |
| 6 | Ergot Derivative [EPC] | 9 | 0.0018 |
| 7 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 9 | 0.0014 |
| 8 | Somatostatin Analog [EPC] | 8 | 0.0012 |
| 9 | Adrenocorticotropic Hormone [EPC] | 1 | 0.0011 |